IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients

First FDA warning letter for nonpayment of GDUFA fee issued against German manufacturer

6:15 AM MDT | October 8, 2013 | Deepti Ramesh

US FDA has issued a warning letter to C.P.M. ContractPharma (Feldkirchen-Westerham, Germany), a contract manufacturing firm, for failing to self-identify and pay its annual fee as required under FDA’s Generic Drug User Fee Amendments of 2012 (GDUFA). The facility has been placed on a publicly available arrears list, FDA says. “Failure to correct these violations promptly may result in regulatory action, including seizure or injunction without further notice; and the facility may also be placed on import alert such that any drug the facility...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week subscriber yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine a year in print or digital format
  • Real time news and analysis on chemweek.com 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now


contact us | about us | privacy policy | sitemap

ihsCopyright © IHS, Inc.All rights reserved.Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa